The Rising Costs of Health Care in Kerala: A Cause for Concern
Introduction
The Kerala Model of healthcare — built on high life expectancy, low infant mortality, and affordable treatment — is facing a structural stress test as global private equity reshapes its hospital landscape.
"A large number of people seeking medical treatment and their willingness to pay could be driving large private equity firms to Kerala." — Dr. A. Althaf, Professor of Community Medicine, GMC Thiruvananthapuram
| Indicator | Figure |
|---|---|
| PE Investment in Kerala Hospitals (recent years) | ₹5,800+ crore |
| Per Capita Private Health Expenditure (2013-14) | ₹7,636 |
| Per Capita Private Health Expenditure (2021-22) | ₹13,343 |
| Private Share of Total Health Expenditure (2021-22) | 59.1% |
Background: The Kerala Model and Its Foundations
Kerala achieved health outcomes comparable to developed nations — life expectancy ~75 years, infant mortality rate of 5 per 1,000 live births (2024) — through a unique combination of:
- Extensive public health infrastructure
- High health literacy and hygiene awareness
- Strong network of small private, cooperative, and charitable hospitals
- Relatively affordable out-of-pocket expenditure
This model succeeded not because of corporate hospitals, but despite their absence — through decentralised, community-level care delivery.
The Corporatisation Wave: Key Data Points
| Transaction | Year | Investor | Amount |
|---|---|---|---|
| KKR acquires 70% stake in Baby Memorial Hospital (BMH), Kozhikode | 2024 | KKR (USA) | ₹2,500 crore |
| Blackstone-backed Quality Care acquires 80% of KIMS Health | 2023 | Blackstone (USA) | ₹3,300 crore |
| Aster DM Healthcare India merges with Quality Care | 2024 | Blackstone | Undisclosed |
| BMH acquires majority stake in Meitra Hospital, Kozhikode | 2025 | KKR (via BMH) | Undisclosed |
| CCI clears Bentley Asia Holdings' additional stake in BMH | March 2026 | Bentley Asia/KKR | Undisclosed |
Corporate hospitals (500+ beds) have grown by at least 65% in the past 10 years in Kerala.
The Other Side: Disappearing Small Hospitals
While large hospitals expand, small private hospitals — the backbone of rural and semi-urban affordable care — are shutting down.
| Period | OP Institutions Closed | IP Institutions Closed |
|---|---|---|
| 2016–2021 | 148 | 262 |
| 2021–2026 | 1,306 | 444 |
Despite closure of small institutions, overall bed count in Kerala rose only marginally — from 80,267 to 82,557 between 2021 and 2026 — indicating that corporate expansion has not compensated for the loss of distributed, affordable care.
Primary cause of closures: Strict enforcement of the Clinical Establishments (Registration and Regulation) Act, 2018 — compliance costs disproportionately burden small operators while large corporates absorb them easily.
Key Analytical Issues
1. Out-of-Pocket Expenditure (OOPE) and Equity
- Private health expenditure share: 76% (2013-14) → 59.1% (2021-22) — a decline, but still high.
- Government share rose from 24% to 32.5% — reflecting increased public investment.
- Yet absolute OOPE per capita nearly doubled in the same period — affordability stress is real.
"A large number of people seeking medical treatment and their willingness to pay could be driving large private equity firms to Kerala." — Dr. A. Althaf, Professor of Community Medicine, GMC Thiruvananthapuram
2. Revenue Targets and Clinical Autonomy
Corporate hospitals impose revenue-linked targets on specialist doctors — quotas for admissions, diagnostic tests, and procedures. This creates perverse incentives:
- Over-investigation and over-treatment
- Erosion of doctor-patient trust
- Rise in violence against healthcare workers
A UN University–International Institute for Global Health (2025) background paper flagged that corporatisation introduces managerial oversight driven by business principles, limiting professional medical autonomy.
3. The Insurance Trap
Corporate expansion is closely tied to health insurance growth. Critics argue this creates an insurance-dependent model where:
- Uninsured patients face denial of care or prohibitive costs
- Hospitals optimise for insured patients with higher billing potential
- Government schemes (like Ayushman Bharat, Karunya Arogya Suraksha Padhathi) become captured by corporate billing practices
4. Elimination of General Practitioners (GPs)
The corporate model favours specialists over family doctors. Kerala's traditional strength — accessible primary care through GPs — is being dismantled, pushing even minor ailments into expensive specialist and tertiary settings.
"Family doctors or general practitioners are the most important doctors in the community for providing primary care. However, they have been eliminated." — Dr. P.K. Sasidharan, Former HoD General Medicine, GMC Kozhikode
Government Response
- Chief Minister flagged rising private healthcare costs publicly — signalling political awareness but limited regulatory action so far.
- Health Minister emphasised strengthening government hospitals with free/subsidised treatment and warned against deliberate patient diversion to corporate hospitals.
- Kerala's Medisep scheme (health insurance for government employees) and KASP (Karunya Arogya Suraksha Padhathi) are attempts to insulate vulnerable populations from OOPE.
Industry Counter-Argument
Harish Manian (Group CEO, BMH) argues:
- Private investment represents adaptation, not commercialisation
- Average Revenue Per Occupied Bed (ARPOB) in Kerala remains the lowest in India despite PE investment
- Scale improves procurement efficiency, governance, and long-term planning
- Healthcare financing will remain hybrid — combining government schemes, insurance, and self-pay
This perspective deserves engagement — not all PE investment leads to price escalation, and governance quality, not capital source, is the real determinant.
Comparison: Corporatisation Models
| Dimension | Kerala (Emerging) | US Model | Thailand Model |
|---|---|---|---|
| Primary Driver | PE consolidation | Insurance-linked corporates | Public-private partnership |
| OOPE Level | High but declining | Very high | Low |
| Access for Poor | Strained | Severely limited | Protected via UHC |
| Regulatory Framework | Weak enforcement | Strong antitrust | Strong public oversight |
| Outcome | Model under stress | High cost, unequal | High quality, equitable |
Implications and Challenges
- Equity erosion: Consolidation concentrates quality care among the affluent and insured, leaving the poor dependent on underfunded public facilities.
- Regulatory vacuum: India lacks a comprehensive law to regulate pricing, clinical standards, and PE participation in healthcare — the Clinical Establishments Act is inadequate.
- NCD burden: Rising diabetes, hypertension, cancers, and mental health issues increase demand for expensive specialist care — a structural driver of corporatisation that public health alone cannot address.
- Ageing population: Kerala's demographic profile — one of India's oldest populations — will sustain demand for costly geriatric and long-term care, further incentivising PE entry.
- CCI's limited role: Competition Commission approvals focus on market dominance, not healthcare equity — a critical gap in regulatory architecture.
Conclusion
Kerala's healthcare paradox — world-class indicators coexisting with rising costs and declining access — is a warning sign for India's broader health governance debate. Private equity investment is not inherently harmful; but without robust regulatory architecture, transparent pricing norms, and a strengthened public health system, corporatisation risks converting a public good into a market commodity. The solution lies not in rejecting private participation but in ensuring that governance, not profit, drives clinical decisions. Strengthening primary care, reviving the GP ecosystem, enforcing the Clinical Establishments Act equitably, and expanding universal health coverage are the policy imperatives — failing which the Kerala Model risks becoming a cautionary tale rather than a template.
Attribution
Original content sources and authors
Syllabus classification
How this article maps to GS papers
Main syllabus
GS2HealthcareQuick Q&A
What are the key features of the Kerala model of health care, and what paradoxes are emerging in its current evolution?
However, recent trends reveal significant paradoxes. Despite a robust public health system, there is increasing dependence on private and corporate hospitals, even for minor ailments. This has led to rising out-of-pocket expenditure, as seen in the anecdote where treatment costs varied drastically between corporate and cooperative hospitals. Additionally, private equity investments are accelerating the corporatisation of healthcare.
This duality creates structural tension: while the public system ensures affordability and equity, the private sector offers advanced care but at higher costs. The decline of small private hospitals and the rise of large corporate chains further deepen inequality. Thus, Kerala’s model is transitioning from a welfare-oriented system to a mixed but increasingly market-driven system, raising concerns about accessibility and affordability.
Why is out-of-pocket health expenditure rising in Kerala despite strong public health indicators?
Key reasons include:
- Rising disease burden: Increasing prevalence of non-communicable diseases (NCDs) such as diabetes, cancer, and hypertension
- Ageing population: Higher proportion of elderly requiring long-term and costly care
- Preference for private care: Perception of better quality and faster service in private hospitals
- Advanced medical technologies: Use of expensive diagnostics and treatments
For example, patients often undergo multiple diagnostic tests in corporate hospitals, significantly increasing costs.
Additionally, systemic factors such as inadequate strengthening of primary care and the decline of small affordable hospitals contribute to this trend. Although government interventions have reduced costs in public hospitals, the growing dominance of private providers means that many households still face financial vulnerability due to medical expenses.
How is corporatisation and private equity investment transforming the healthcare landscape in Kerala?
Key transformations include:
- Hospital consolidation: Smaller hospitals are being acquired or replaced by large corporate chains
- Advanced infrastructure: Investment in modern diagnostics, digital systems, and specialised care
- Managerial practices: Introduction of business-oriented governance and performance targets
For instance, the acquisition of Baby Memorial Hospital and mergers involving Aster DM Healthcare illustrate the scale of consolidation.
However, this transformation has mixed implications. While it improves quality and access to advanced care, it also introduces profit-driven practices, such as revenue-linked targets for doctors. This can lead to over-prescription of tests and treatments, raising costs. Thus, corporatisation is reshaping Kerala’s healthcare into a more capital-intensive and market-driven system, necessitating regulatory oversight.
What are the reasons behind the closure of small private hospitals in Kerala, and what are its implications?
Key reasons include:
- Strict regulatory norms: Compliance with the Clinical Establishments Act increases operational costs
- Competition from corporate hospitals: Larger institutions attract patients with advanced facilities
- Financial constraints: Smaller hospitals struggle to invest in modern equipment and specialist staff
For example, many 20-bed hospitals in rural areas have either closed or scaled down due to inability to compete with corporate chains.
The implications are गंभीर:
- Reduced accessibility: ग्रामीण and semi-urban populations lose nearby affordable healthcare options
- Increased burden on public hospitals: More patients shift to government facilities
- Healthcare inequality: Gap widens between urban and rural healthcare access
This trend highlights the need for policies that support small and medium healthcare providers to maintain a balanced and inclusive healthcare ecosystem.
Critically analyse the impact of corporatisation on doctor–patient relationships and healthcare ethics.
Negative impacts include:
- Reduced autonomy: Doctors may face pressure to meet revenue targets
- Over-medicalisation: Increased use of diagnostic tests and procedures
- Erosion of trust: Patients may perceive treatment as profit-driven
For instance, anecdotal evidence suggests that unnecessary tests are sometimes prescribed in corporate settings, raising ethical concerns.
However, there are also positive aspects:
- Improved infrastructure: Access to advanced medical technology
- Standardised care protocols: Better quality control and outcomes
The challenge lies in balancing efficiency with ethics. Strong regulatory frameworks, transparent pricing, and emphasis on medical ethics are essential to ensure that corporatisation does not undermine the core objective of healthcare—patient welfare.
As a public health policymaker, how would you address the challenges of rising healthcare costs and corporatisation in Kerala?
Key policy interventions would include:
- Strengthening public healthcare: Invest in infrastructure, staffing, and advanced treatment options in government hospitals
- Regulating private sector: Implement price caps and standard treatment guidelines
- Promoting insurance coverage: Expand schemes to reduce out-of-pocket expenditure
- Supporting small hospitals: Provide financial incentives and regulatory relaxation
For example, schemes like Medisep and other insurance programmes can provide financial protection to patients.
Preventive healthcare must be prioritised by strengthening primary care and promoting healthy lifestyles to reduce disease burden. Additionally, ensuring transparency in pricing and accountability in private hospitals can build trust.
Ultimately, Kerala must preserve its legacy of equitable healthcare while adapting to modern challenges, creating a balanced system that integrates public leadership with responsible private participation.
Practice questions
2 questions for mains preparation